Patricia Coyle from Stony Brook University: Bringing Lessons From ACTRIMS Back to Practice
Some of the finest minds in the field of multiple sclerosis were in New Orleans for the annual ACTRIMS conference all looking to share their knowledge and learn more before returning home to their patients.
Gregory Wu From Washington University: B Cells and More In Progressive MS Treatment Development
As researchers focus on finding treatments for progressive multiple sclerosis there are a number of potential angles to study to find the best treatment options possible. One potential area is the role of B cells in the treatment process.
Mark Freedman From University of Ottawa: Progressive Multiple Sclerosis Treatment a Work In Progress
As the first medication designed to treat primary progressive multiple sclerosis moves closer to the market there are still many questions about how effective it will be and what other treatment options may look like in the future.
Is Ovarian Decline Associated with Clinical Disability in Female MS Patients?
Prior research has shown women suffering from multiple sclerosis (MS) often have a more benign initial course than male patients. However, these same female patients tend to quickly transition to secondary progressive disease as their approach menopause.
MS Patients Willing to Change Diet, Survey Found
Obesity, along with the composition of the microbiome in the gut, have been suggested as being elements that may contribute to the risk of multiple sclerosis. Patients surveyed said they would be willing to change diet to see if it helped their illness.
ACTRIMS President Sees Hope for Future Progressive MS Treatment
For many years there were no approved treatments for patients with primary progressive multiple sclerosis. Recently, a concerted effort has been made to change that and get this patient population the help they so badly need.
Potential New Therapy for Patients with Relapsing Multiple Sclerosis
Results from the RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modulators for relapsing multiple sclerosis (MS) patients showed significant reductions in the cumulative number of total gadolinium-enhancing (GdE) lesions.